As a consequence of resurgence of interest and a significant increase in active intervention for patients with colorectal liver metastases, numerous policies for such patients are available, and many clinicians are confused by the plethora of therapeutic permutations and combinations. Colorectal cancer is common and the most frequent site of recurrence (and subsequent mortality) is the liver. It is important however to distinguish between established policies and experimental treatments undergoing Phase I-II evaluations. This article reviews available management options.
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Screening for liver metastases
This has been suggested on the basis that the recognition of an operable solitary liver metastasis might enable resection to occur and survival benefit to accrue. Unfortunately this argument is spurious.
It is by no means certain that asymptomatic diagnosis enhances survival, because of the effect of lead-time bias. Only a randomized trial can show this. A 
